Sitemap

Company
  1. Who We Are
    1. Global Organization
    2. History
    3. Our Leadership Team
      1. Chris Round
      2. Miguel Fernández Alcalde
      3. Kate Cingolani
      4. Bob Dean
      5. BoonHuey Ee
      6. Eduardo Fabiano
      7. Betania Glorio
      8. Libby Horne
      9. Lori Lebson
      10. Michael MacDougall
      11. Terri Stewart
      12. Venkat Thiruvallur
      13. Sarah Turner
      14. Joel VanderMeulen
      15. Dan Van Horn
      16. Lisa Walsh
  3. Vibrant Thoughts Blog
    1. Cycling Inspiration Through the Community
    2. Remembering the Hopes and Dreams of Future Fathers
    3. Clinical Trials Won’t Ever Be the Same & Why That’s a Good Thing
    4. COVID’s Costs on Workplace Equality – How Women Have Overpaid
    5. A Gathering of the Minds to Help Generations to Come
    6. Kick Starting 2022
    7. “I’M IN” to Deliver on Diversity for Patients
    8. Small Steps Make a Big Impact: Moving from Conservation to Sustainability
    9. 31 Days to Recognize Bladder Cancer Awareness Month
    10. Top 5 Family-Building Tips for LGBTQ+ Communities
    11. Finding the Value in VBCs
    12. 25+ Years of Commitment… and Still Going Strong for the HIV Community
    13. WE WILL Deliver on Our Future
    14. Community Matters in Multiple Sclerosis
    15. “Moving” to Support Those with Head and Neck Cancer
    16. Our Military and Veterans Deserve to Build Their Families
    17. Making Patient-Directed the “New Normal”
    18. Reflecting on a Childhood Love for Science this "Back to School" Season
    19. Who's Caring for the Carer?
    20. Powering Our Future in the Seaport
    21. Destigmatizing the Most Stigmatized Diseases
  5. Contact Us
  6. Partnering
  7. Corporate Responsibility
    1. Embracing Carers
    2. Healthy Women, Healthy Economies
    3. Environmental Commitment
    4. Corporate Giving
    5. Patient Safety
  9. News
    1. Press Releases
      1. 2024-11-12 Pimicotinib Significantly Improved Outcomes for Patients with TGCT in Phase III Trial
      2. 2024-09-12 ECTRIMS 2024
      3. 2024-08-29 MyClad Phase III Update
      4. 2024-06-24 Merck KGaA, Darmstadt, Germany, Provides Update on Xevinapant Program
      5. 2024-06-03 Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment
      6. 2024-05-23 Advances in the Science of Cancer With New Data Presented at ASCO 2024
      7. 2024-02-29 ACTRIMS 2024
      8. 2024-01-22 ASCO Genitourinary Cancers Symposium 2024
      9. 2024-01-04 Merck KGaA, Darmstadt, Germany, Expands Colorectal Cancer Portfolio
      10. 2023-12-05 Merck KGaA, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis
      11. 2023-12-04 Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib
      12. 2023-11-14 EMD Serono Announces Plans for New U.S. Healthcare Headquarters in Boston’s Seaport District
      13. 2023-10-30 Merck KGaA, Darmstadt, Germany, Strengthens Oncology Pipeline
      14. 2023-10-16 EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023
      15. 2023-10-11 Evobrutinib Has Shown Sustained Clinical Benefit Up to Five Years in People with RMS
      16. 2023-10-10 New MAVENCLAD® (Cladribine) Tablets Data Highlighting Sustained Reduction in NfLs and Benefit of Early Initiation
      17. 2023-10-05 EMD Serono Launches Collaboration with UN-Guided Global Initiative on Ageing
      18. 2023-05-25 ASCO 2023 Highlights
      19. 2023-03-27 Merck KGaA, Darmstadt, Germany Regains Exclusive Worldwide Rights to BAVENCIO®
      20. 2023-02-23 ACTRIMS 2023
      21. 2023-02-13 New Analyses Reinforce Survival Benefit of BAVENCIO
      22. 2022-12-22 Mersana ADC Collaboration
      23. 2022-11-21 Research and Development Update
      24. 2022-10-26 New Data for Evobrutinib
      25. 2022-10-26 EMD Serono Showcases Depth of MS Portfolio at ECTRIMS
      26. 2022-09-21 Nerviano Collaboration
      27. 2022-09-07 ESMO 2022 xevinapant Five Year Data
      28. 2022-09-07 EMD Serono to Highlight Data at ESMO 2022
      29. 2022-06-04 EMD Serono advances development programs in oncology
      30. 2022-05-26 ASCO 2022 Highlights
      31. 2022-03-31 Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022
      32. 2022-02-24 New MAVENCLAD® Data at ACTRIMS Forum 2022
      33. 2022-02-18 TEPMETKO® for Patients with Advanced NSCLC with METex14 Skipping Alterations
      34. 2022-02-18 BAVENCIO® First-Line Maintenance Treatment of Advanced UC Patients
      35. 2022-02-17 Sustainable Slim Pack for Fertility Medication
      36. 2021-12-17 TEPMETKO receives positive CHMP opinion
      37. 2021-11-29 EMD Serono Launches New Fertility LifeLines™ Portal
      38. 2021-11-17 New Data Show Dramatic Emotional Toll of Pandemic on Unpaid Caregivers of Peopl
      39. 2021-10-14 New Data Presented at ECTRIMS Show Evobrutinib
      40. 2021-10-13 New Real-World MAVENCLAD® Data
      41. 2021-10-04 EMD Serono Completes Enrollment of Evobrutinib ECTRIMS 2021
      42. 2021-09-13 ESMO WCLC 2021 Highlights
      43. 2021-05-19 ASCO21 Data
      44. 2021-04-23 New Data for MAVENCLAD® Use During the COVID-19 Pandemic
      45. 2021-04-16 Evobrutinib is the First and Only BTK Inhibitor
      46. 2021-04-12 EMD Serono Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer
      47. 2021-03-16 Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer
      48. 2021-03-01 Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
      49. 2021-02-25 New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients
      50. 2021-02-09 Real-World Evidence Study at Miami CFAR Suggests HIV-Associated Wasting Remains an Underappreciated Comorbidity
      51. 2021-02-04 Merck KGaA, Darmstadt, Germany, Announces Leadership Change for North America and Global Innovative Medicine Franchises in Healthcare
      52. 2021-02-03 FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations
      53. 2021-01-25 European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment
      54. 2021-01-20 Merck KGaA, Darmstadt, Germany Announces Update on the INTR@PID Clinical Program Including Lung 037 Study
      55. 2020-12-11 BAVENCIO® (avelumab) Receives Positive CHMP Opinion
      56. 2020-11-18 EMD Serono's Embracing Carers™ Announces Study Results on COVID-19 and Caregive
      57. 2020-10-15 EMD Serono Announces Retirement of Dr. Luciano Rossetti
      58. 2020-09-18 BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published
      59. 2020-09-13 ESMO 2020 - Oncology Portfolio and Pipeline with Data in Multiple Cancers
      60. 2020-09-11 Merck KGaA - Positive Phase II Results for Investigational Sonelokinab (M1095)
      61. 2020-09-03 EMD Serono - New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting
      62. 2020-08-25 FDA Accepts Filing of New Drug Application for Tepotinib
      63. 2020-08-05 EMD Serono statement on Rebif® (interferon beta-1a) for the ACTT 3 trial
      64. 2020-06-30 FDA Approves BAVENCIO as First-Line Maintenance Treatment
      65. 2020-06-25 First Clinical Trial of TLR7 and 8 Inhibitor as a Potential Treatment for Sever
      66. 2020-06-08 EMD Serono Announces Launch of MS in the 21st Century Website
      67. 2020-05-29 New England Journal of Medicine: Primary Analysis of VISION Data for Tepotinib
      68. 2020-05-28 Merck KGaAand Twitch Join Forces on World Multiple Sclerosis Day
      69. 2020-05-27 Rebif® U.S. Label Now Includes Pregnancy Outcomes and Lactation Information
      70. 2020-05-23 Evobrutinib First BTK Inhibitor to Report Efficacy+Safety in MS Over 108 Weeks
      71. 2020-05-13 Breakthrough Innovation in Cancer Care to Be Presented at ASCO 2020
      72. 2022-04-30 EMD Serono - ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care
      73. 2020-04-09 EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO®
      74. 2020-03-25 TEPMETKO® (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations
      75. 2020-03-19 Combating the Spread of COVID-19
      76. 2020-03-18 2020-03-18 Merck KGaA statement updates for the INTR@PID Lung 037 study
      77. 2020-03-13 EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
      78. 2020-01-09 EMD Serono and MyHealthTeams Launch Family Planning Resource Center to Provide Families Affected by Multiple Sclerosis
      79. 2020-01-06 BAVENCIO Improved Overall Survival in Patients With Urothelial Carcinoma
    3. Download Gallery
      1. Sites & Buildings
        1. EMD Serono R&D Institute, Billerica, MA - Company Logo on Building
        2. EMD Serono R&D Institute, Billerica, MA - Aerial View
        3. EMD Serono R&D Institute, Billerica, MA - Cafeteria Booths
        4. EMD Serono R&D Institute, Billerica, MA - Cafeteria
        5. EMD Serono R&D Institute, Billerica, MA - Laboratory
        6. EMD Serono R&D Institute, Billerica, MA - Sculpture
      3. Logos
        1. EMD Serono Logo Red
        2. EMD Serono Logo Cyan
        3. EMD Serono Logo Yellow
      5. b-roll
        1. EMD Serono R&D Institute, Billerica, MA - B-Roll
    5. Press Release Archive
Expertise
Research
Careers
Patients and Caregivers
Compliance & Transparency
Sitemap